Cassava Sciences Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Cassava Sciences.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Pharmaceuticals earnings growth | 14.4% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | None |
| Last updated | n/a |
Recent future growth updates
Recent updates
Cassava: Low-Cost Pivot Into TSC Epilepsy Is Unlikely To Create Long-Term Value
Mar 04Cassava Q3 Earnings Review: It Feels Like The End May Be Nigh
Nov 07Cassava Sciences: Turning The Corner Into A Brick Wall
Jul 24Cassava Sciences (NASDAQ:SAVA) Is In A Good Position To Deliver On Growth Plans
Oct 17
We're Hopeful That Cassava Sciences (NASDAQ:SAVA) Will Use Its Cash Wisely
Jul 04We're Not Very Worried About Cassava Sciences' (NASDAQ:SAVA) Cash Burn Rate
Mar 05Cassava Sciences (NASDAQ:SAVA) Is In A Good Position To Deliver On Growth Plans
Nov 19Cassava Sciences begins extension study of Alzheimer's drug simufilam
Oct 13Cassava Sciences Stock: Huge Returns Or Catastrophic Losses
Sep 29Cassava Sciences: Trying To Manage Expectations
Sep 21Cassava Sciences reaches over five-month high on rising volumes
Sep 09Cassava Sciences Looks As Good Of A Purchase As Ever
Sep 03Cassava Sciences stock jumps 10% after director buys $860K shares
Aug 26Cassava Sciences rally continues as stock up 39%
Aug 17Cassava's Simufilam And Acetylcholinesterase Inhibitors: Similar Results
Aug 11Cassava Sciences GAAP EPS of -$0.48 misses by $0.06
Aug 03We're Hopeful That Cassava Sciences (NASDAQ:SAVA) Will Use Its Cash Wisely
Aug 03Cassava Sciences sheds 44% on report of criminal probe linked to Alzheimer’s drug
Jul 27Cassava Sciences And Alzheimer's Disease: A Precipitious Path
Jun 10Cassava Sciences: 3 Upcoming Catalysts That Could Decide Bull / Bear Debate
May 31Cassava Sciences (NASDAQ:SAVA) has More Than Enough Funding to Function Until the Approval Process is Finished, but Investors may Need to be Ready for a Long Wait
Apr 193 Key Points To Remember About Cassava Sciences
Apr 07Retractions Of A Key Collaborator's Papers Set Up A Big April For Cassava Sciences
Mar 31In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Cassava Sciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 3/31/2025 | N/A | -73 | -109 | -109 | N/A |
| 12/31/2024 | N/A | -24 | -117 | -117 | N/A |
| 9/30/2024 | N/A | -18 | -78 | -78 | N/A |
| 6/30/2024 | N/A | -15 | -86 | -86 | N/A |
| 3/31/2024 | N/A | -48 | -88 | -88 | N/A |
| 12/31/2023 | N/A | -97 | -82 | -82 | N/A |
| 9/30/2023 | N/A | -95 | -81 | -81 | N/A |
| 6/30/2023 | N/A | -90 | -77 | -76 | N/A |
| 3/31/2023 | N/A | -83 | -70 | -67 | N/A |
| 12/31/2022 | N/A | -76 | -80 | -78 | N/A |
| 9/30/2022 | N/A | -71 | -67 | -64 | N/A |
| 6/30/2022 | N/A | -61 | -81 | -57 | N/A |
| 3/31/2022 | N/A | -46 | -74 | -51 | N/A |
| 12/31/2021 | N/A | -32 | -52 | -30 | N/A |
| 9/30/2021 | N/A | -21 | -45 | -23 | N/A |
| 6/30/2021 | N/A | -13 | -11 | -11 | N/A |
| 3/31/2021 | N/A | -9 | -6 | -6 | N/A |
| 12/31/2020 | N/A | -6 | -5 | -5 | N/A |
| 9/30/2020 | N/A | -5 | -5 | -5 | N/A |
| 6/30/2020 | N/A | -4 | -3 | -3 | N/A |
| 3/31/2020 | N/A | -4 | -3 | -3 | N/A |
| 12/31/2019 | N/A | -5 | -3 | -3 | N/A |
| 9/30/2019 | N/A | -4 | -3 | -2 | N/A |
| 6/30/2019 | N/A | -4 | -3 | -3 | N/A |
| 3/31/2019 | N/A | -6 | -4 | -4 | N/A |
| 12/31/2018 | N/A | -7 | N/A | -5 | N/A |
| 9/30/2018 | N/A | -8 | N/A | -6 | N/A |
| 6/30/2018 | N/A | -10 | N/A | -6 | N/A |
| 3/31/2018 | N/A | -11 | N/A | -8 | N/A |
| 12/31/2017 | N/A | -12 | N/A | -8 | N/A |
| 9/30/2017 | N/A | -12 | N/A | -10 | N/A |
| 6/30/2017 | N/A | -13 | N/A | -10 | N/A |
| 3/31/2017 | N/A | -12 | N/A | -11 | N/A |
| 12/31/2016 | N/A | -15 | N/A | -12 | N/A |
| 9/30/2016 | N/A | -17 | N/A | -13 | N/A |
| 6/30/2016 | N/A | -17 | N/A | -12 | N/A |
| 3/31/2016 | N/A | -17 | N/A | -11 | N/A |
| 12/31/2015 | N/A | -14 | N/A | -9 | N/A |
| 9/30/2015 | N/A | -12 | N/A | -8 | N/A |
| 6/30/2015 | N/A | -12 | N/A | -7 | N/A |
| 3/31/2015 | N/A | -12 | N/A | -8 | N/A |
| 12/31/2014 | N/A | -12 | N/A | -10 | N/A |
| 9/30/2014 | 35 | 23 | N/A | -8 | N/A |
| 6/30/2014 | 37 | 26 | N/A | -9 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if SAVA's forecast earnings growth is above the savings rate (2.9%).
Earnings vs Market: Insufficient data to determine if SAVA's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if SAVA's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if SAVA's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if SAVA's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SAVA's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/05 22:26 |
| End of Day Share Price | 2025/06/05 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cassava Sciences, Inc. is covered by 7 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gregory Fraser | BofA Global Research |
| Mayank Mamtani | B. Riley Securities, Inc. |
| Kenneth Trbovich | C. K. Cooper & Company, Inc. |